Opening for Project Assistant Level-I in Central Salt & Marine Chemicals Research Institute

With a coastline of about 3,500 miles, inland sources in Rajasthan and Little Rann of Kutch, and the rock salt mines in Mandi, India have possibilities of attaining a high position in salt production among the salt producing countries of the world. As is known, apart from being an indispensable item of food, salt is an important raw material for the manufacture of several heavy chemicals e.g. soda ash, caustic soda and chlorine. Besides, salt is used in food processing industries, such as fish curing, meat packing, dairy products and fruit and vegetable canning.

Athenex, Inc. announced  that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex’s sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer drugs, one ointment) and the third such clinical drug candidate in Athenex’s oral absorption platform. Docetaxel is an established and effective high potency anti-cancer drug.

U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Shire plc announced that it has completed its acquisition of Dyax Corp. in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.

XTL Biopharmaceuticals, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, announced the Company has received written guidance from the U.S. Food and Drug Administration (FDA) in response to a pre-investigational new drug (IND) meeting package regarding its upcoming IND filing for its drug candidate, hCDR1. Based on the FDA's response, XTL plans to file its IND, and in the coming quarters initiate a global clinical trial for hCDR1 in the treatment of systemic lupus erythematosus (SLE) in the U.S., Europe and Israel.

Biocon Ltd, Asia's premier biotechnology company, today announced key data on Insulin Tregopil (formerly referred to as IN-105) following Phase 1 studies that validate and provide the basis for the next phase of clinical development of this important molecule. The clinical studies on Insulin Tregopil, which were conducted in the US under a US IND, were initiated in partnership with Bristol-Myers Squibb (BMS) prior to their divestment of the diabetes franchise to AstraZeneca.

A hand-held, miniature microscope roughly the size of a pen can allow surgeons to "see" at a cellular level in the operating room and determine where to stop cutting the tumour to kill only cancerous cells and protect healthy cells.